Small molecules targeting severe acute respiratory syndrome human coronavirus.
暂无分享,去创建一个
Hsuan-Cheng Huang | Hsueh-Fen Juan | Po-Huang Liang | Chung-Yi Wu | Chi-Huey Wong | Chih-Jung Kuo | Ashraf Brik | Chi‐Huey Wong | H. Juan | Hsuan-Cheng Huang | Shui-Tein Chen | A. Brik | Chung-Yi Wu | J. Jan | Jim-Min Fang | Yih-Shyun E. Cheng | P. Liang | C. Kuo | Shiou-Hwa Ma | Hsien-Hua Hsu | Douglass Wu | F. Liang | Rai‐Shung Liu | Shui-Tein Chen | Douglass Wu | Jim-Min Fang | Jia-Tsrong Jan | Shiou-Hwa Ma | Yih-Shyun E Cheng | Hsien-Hua Hsu | Fu-Sen Liang | Rai-Shung Liu | Hsueh‐Fen Juan
[1] K. Wilhelm,et al. [Thermometric investigations about the efficacy of beta-escin to reduce postoperative edema (author's transl)]. , 1977, Medizinische Klinik.
[2] M. Chan-yeung,et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.
[3] M. Burkart. Metabolic engineering--a genetic toolbox for small molecule organic synthesis. , 2003, Organic & biomolecular chemistry.
[4] Young Joo Lee,et al. Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells , 2003, Archives of pharmacal research.
[5] Guoping Zhao,et al. Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China , 2004, Science.
[6] S. Y. Chan,et al. Effect of reserpine on fertilizing capacity of human spermatozoa. , 1984, Contraception.
[7] H. Fraser. Reserpine: A tragic victim of myths, marketing, and fashionable prescribing , 1996, Clinical pharmacology and therapeutics.
[8] Obi L. Griffith,et al. The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.
[9] Chi‐Huey Wong,et al. A quick diversity-oriented amide-forming reaction to optimize P-subsite residues of HIV protease inhibitors. , 2002, Chemistry & biology.
[10] J. A. Comer,et al. A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[11] C. Crumpacker,et al. The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry. , 1998, Virology.
[12] P. Bakker,et al. Suppression of Soil-Borne Plant Pathogens by Fluorescent Pseudomonads: Mechanisms and Prospects , 1991 .
[13] M. Höfte. 1 – CLASSES OF MICROBIAL SIDEROPHORES , 1993 .
[14] L. Poon,et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .
[15] Christian Drosten,et al. Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.
[16] Luhua Lai,et al. Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase* , 2004, Journal of Biological Chemistry.
[17] Arthur S Slutsky,et al. Identification of severe acute respiratory syndrome in Canada. , 2003, The New England journal of medicine.
[18] J. Hsu,et al. Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate , 2004, Biochemical and Biophysical Research Communications.
[19] H. Doerr,et al. Treatment of SARS with human interferons , 2003, The Lancet.
[20] J. McCubrey,et al. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. , 1993, Journal of immunological methods.
[21] Y. Liu,et al. 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. , 2004, Biochemistry.
[22] Shiow-Chwen Tsai,et al. Stimulation of the secretion of luteinizing hormone by ginsenoside-Rb1 in male rats. , 2003, The Chinese journal of physiology.
[23] M. Chan-yeung,et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. , 2003, American journal of respiratory and critical care medicine.
[24] Rolf Hilgenfeld,et al. Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.
[25] C. Pieterse,et al. Emerging technologies / Technologies naissantes Understanding the involvement of rhizobacteria- mediated induction of systemic resistance in biocontrol of plant diseases , 2003 .
[26] Y. Guan,et al. Coronavirus as a possible cause of severe acute respiratory syndrome , 2003, The Lancet.
[27] K. Yuen,et al. Development of a standard treatment protocol for severe acute respiratory syndrome , 2003, The Lancet.
[28] Á. Muñoz-Fernández,et al. Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered. , 2003, Medical science monitor : international medical journal of experimental and clinical research.
[29] A. Velázquez‐Campoy,et al. Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. , 2004, Biochemistry.
[30] John L. Sullivan,et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.
[31] R. Reiter,et al. Urgent search for safe and effective treatments of severe acute respiratory syndrome: is melatonin a promising candidate drug? , 2003, Journal of pineal research.
[32] Chi‐Huey Wong,et al. Rapid diversity-oriented synthesis in microtiter plates for in situ screening: discovery of potent and selective alpha-fucosidase inhibitors. , 2003, Angewandte Chemie.
[33] W. Seto,et al. Severe acute respiratory syndrome: scientific and anecdotal evidence for drug treatment. , 2004, Current opinion in investigational drugs.
[34] C. Sirtori. Aescin: pharmacology, pharmacokinetics and therapeutic profile. , 2001, Pharmacological research.
[35] H. Hemilä. Vitamin C and SARS coronavirus , 2003, The Journal of antimicrobial chemotherapy.
[36] Philip M. Long,et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection , 2003, The Lancet.
[37] Elizabeth Rea,et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.
[38] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .
[39] E. Dejana,et al. Platelet-neutrophil interactions. Possible relevance in the pathogenesis of thrombosis and inflammation. , 1991, Haematologica.
[40] H. Doerr,et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus , 2003, The Lancet.
[41] Y. Chan,et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS) , 2003, Thorax.
[42] G. Gao,et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[43] Peter Cameron,et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.
[44] R. Frick. Three Treatments for Chronic Venous Insufficiency: Escin, Hydroxyethylrutoside, and Daflon , 2000, Angiology.
[45] S. Lai,et al. Severe Acute Respiratory Syndrome: Clinical Outcome and Prognostic Correlates , 2003, Emerging infectious diseases.
[46] N. Sperelakis,et al. Valinomycin blockade of slow channels in guinea pig hearts perfused with elevated D plus and isoproterenol. , 1974, European journal of pharmacology.
[47] Yeong Shik Kim,et al. Ginsenoside RB1 the anti-ulcer constituent from the head ofPanax ginseng , 2003, Archives of pharmacal research.